Predict your next investment

Venture Capital
deerfield.com

See what CB Insights has to offer

Investments

261

Portfolio Exits

97

Funds

6

Partners & Customers

10

About Deerfield Management

Deerfield Management is an investment firm that seeks to advance healthcare through investment, information and philanthropy.

Deerfield Management Headquarter Location

780 Third Avenue 37th Floor

New York, New York, 10017,

United States

215-551-1600

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Deerfield Management

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Find Deerfield Management in 2 Expert Collections, including Synthetic Biology.

S

Synthetic Biology

382 items

C

CB Insights Healthcare Smart Money Investors - 2020

25 items

Track the world's top-performing VC investors in healthcare. Firms are presented in alphabetical order.

Research containing Deerfield Management

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Deerfield Management in 4 CB Insights research briefs, most recently on Feb 16, 2021.

Latest Deerfield Management News

Illumina, Deerfield Ink Drug Development Deal

May 16, 2022

Illumina, Deerfield Ink Drug Development Deal   On May 5, the San Diego DNA sequencing giant announced a partnership with New York-based healthcare investment management firm Deerfield Management to apply a genetic-led approach to develop novel therapies for diseases with unmet medical needs. Alex AravanisCTOIllumina The five-year partnership will leverage Illumina’s genomic tools and data with Deerfield’s operational and financial expertise managing $14 billion in AUM (assets under management) across 200 public and private portfolio companies – many in the therapeutic space – to guide successful candidates through clinical development. Under the terms of the partnership with Deerfield, Illumina will provide a DNA-driven target discovery platform alongside its AI-powered genome interpretation software while Deerfield will provide expertise in translational science and help guide new drug candidates through preclinical testing. “This partnership serves as a new company (NewCo) creation engine where Illumina and Deerfield will jointly decide whether to progress validated targets into pre-clinical development, at which point a NewCo will be formed,” said Illumina CTO Alex Aravanis. “It is a co-ownership model that gives both Illumina and Deerfield equity in the NewCo, generating drug target assets with long-term optionality that includes royalties if a drug reaches the market,” Aravanis added. “The partnership is openly structured where both parties are aligned in near and long-term success.”   Joydeep GoswamiChief Strategy and Corporate Development OfficerIllumina Illumina Chief Strategy and Corporate Development Officer Joydeep Goswami said this is due to “gaps in the biological understanding of the complex nature of many diseases” and a drug discovery process that is “difficult, expensive and slow.”   Goswami pointed out that Deerfield VP of Genetics and Genomics Matt Nelson’s paper published in “Nature” supported using genetic data to select the best targets and indications in discovery and can improve success rates, speed to market, and cost in the development of new drugs. “Our partnership will work to create efficiencies across the drug development process, through data and AI, and change how we can bring novel therapeutics to market, overcoming the hurdles traditional models have failed to overcome,” Aravanis added. “Leveraging Illumina’s sequencing platform to grow data assets at massive scale, our best-in-class AI tools to interpret the genome and Deerfield’s deep scientific and investment expertise in the therapeutics space, we believe this is a unique engine to industrialize drug development.”   Illumina and Deerfield plan to identify therapeutic targets using Illumina’s genetically driven target discovery platform built with Illumina Connected Analytics and AI-driven genome interpretation solutions. James FlynnManaging PartnerDeerfield Management “Illumina is an innovative global leader in genomics,” said Deerfield Management Managing Partner James Flynn. “Together, with Deerfield’s expertise in translational research, the partnership will fuel advancements from idea to clinic more efficiently with the goal of treating some of the world’s most life-threatening diseases.”

Deerfield Management Investments

261 Investments

Deerfield Management has made 261 investments. Their latest investment was in Apertura Gene Therapy as part of their Series A on April 4, 2022.

CBI Logo

Deerfield Management Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

4/26/2022

Series A

Apertura Gene Therapy

$67M

Yes

2

4/12/2022

Series A

Aurion Biotech

$120M

Yes

6

2/24/2022

Series A - II

Vibliome Therapeutics

$22M

No

1

2/23/2022

Series E

Subscribe to see more

$99M

Subscribe to see more

10

2/3/2022

Series B

Subscribe to see more

$99M

Subscribe to see more

10

Date

4/26/2022

4/12/2022

2/24/2022

2/23/2022

2/3/2022

Round

Series A

Series A

Series A - II

Series E

Series B

Company

Apertura Gene Therapy

Aurion Biotech

Vibliome Therapeutics

Subscribe to see more

Subscribe to see more

Amount

$67M

$120M

$22M

$99M

$99M

New?

Yes

Yes

No

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

2

6

1

10

10

Deerfield Management Portfolio Exits

97 Portfolio Exits

Deerfield Management has 97 portfolio exits. Their latest portfolio exit was PepGen on May 06, 2022.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

5/6/2022

IPO

1

4/29/2022

IPO

5

12/13/2021

Acq - P2P

$99M

5

11/8/2021

Acq - Pending

Subscribe to see more

$99M

Subscribe to see more

10

10/22/2021

IPO

Subscribe to see more

Subscribe to see more

10

Date

5/6/2022

4/29/2022

12/13/2021

11/8/2021

10/22/2021

Exit

IPO

IPO

Acq - P2P

Acq - Pending

IPO

Companies

Subscribe to see more

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Subscribe to see more

Subscribe to see more

Sources

1

5

5

10

10

Deerfield Management Acquisitions

2 Acquisitions

Deerfield Management acquired 2 companies. Their latest acquisition was Endologix on October 01, 2020.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

10/1/2020

Debt

$99M

$177.5M

Take Private

3

10/2/2017

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/1/2020

10/2/2017

Investment Stage

Debt

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$177.5M

Note

Take Private

Subscribe to see more

Sources

3

10

Deerfield Management Fund History

6 Fund Histories

Deerfield Management has 6 funds, including Deerfield Healthcare Venture Fund.

Closing Date

Fund

Fund Type

Status

Amount

Sources

4/6/2020

Deerfield Healthcare Venture Fund

$840M

1

11/25/2016

Deerfield Private Design Fund IV

Subscribe to see more

Subscribe to see more

$99M

10

7/28/2015

Deerfield Healthcare Innovations Fund

Subscribe to see more

Subscribe to see more

$99M

10

4/7/2014

Deerfield Private Design Fund III

Subscribe to see more

Subscribe to see more

$99M

10

Deerfield Healthcare Innovations Fund II

Subscribe to see more

Subscribe to see more

$99M

10

Closing Date

4/6/2020

11/25/2016

7/28/2015

4/7/2014

Fund

Deerfield Healthcare Venture Fund

Deerfield Private Design Fund IV

Deerfield Healthcare Innovations Fund

Deerfield Private Design Fund III

Deerfield Healthcare Innovations Fund II

Fund Type

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$840M

$99M

$99M

$99M

$99M

Sources

1

10

10

10

10

Deerfield Management Partners & Customers

10 Partners and customers

Deerfield Management has 10 strategic partners and customers. Deerfield Management recently partnered with Illumina on May 5, 2022.

Date

Type

Business Partner

Country

News Snippet

Sources

5/5/2022

Partner

United States

09:15 EDT Illumina and Deerfield Management partner to accelerate drug development

Illumina , Inc. and Deerfield Management today announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs .

3

1/18/2022

Partner

United States

Deerfield and Stanford University Create the Porter Alliance for Innovative Medicines

SAN FRANCISCO & NEW YORK -- -- Stanford University School of Medicine and Deerfield Management , a healthcare investment firm , have collaborated to create Porter Alliance for Innovative Medicines to accelerate translational research into clinical therapeutics .

1

11/24/2020

Partner

India

Contract Pharma Staff11.24.20. Syngene And 3DC Sign 5-year Collaboration - Contract Pharma

Syngene International and Deerfield Discovery and Development Corporation , the drug discovery and development subsidiary of Deerfield Management Company , have signed an agreement to collaborate to advance therapeutic discovery projects , from target validation through to pharmacological proof of concept and preclinical evaluation .

1

11/19/2020

Partner

India

Subscribe to see more

Subscribe to see more

10

6/5/2019

Partner

United States

Subscribe to see more

Subscribe to see more

10

Date

5/5/2022

1/18/2022

11/24/2020

11/19/2020

6/5/2019

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

United States

United States

India

India

United States

News Snippet

09:15 EDT Illumina and Deerfield Management partner to accelerate drug development

Illumina , Inc. and Deerfield Management today announced a five-year partnership to apply a genetic-led approach to the discovery and development of novel therapies for diseases with unmet medical needs .

Deerfield and Stanford University Create the Porter Alliance for Innovative Medicines

SAN FRANCISCO & NEW YORK -- -- Stanford University School of Medicine and Deerfield Management , a healthcare investment firm , have collaborated to create Porter Alliance for Innovative Medicines to accelerate translational research into clinical therapeutics .

Contract Pharma Staff11.24.20. Syngene And 3DC Sign 5-year Collaboration - Contract Pharma

Syngene International and Deerfield Discovery and Development Corporation , the drug discovery and development subsidiary of Deerfield Management Company , have signed an agreement to collaborate to advance therapeutic discovery projects , from target validation through to pharmacological proof of concept and preclinical evaluation .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

3

1

1

10

10

Deerfield Management Team

10 Team Members

Deerfield Management has 10 team members, including current Chief Executive Officer, Michael A Foley.

Name

Work History

Title

Status

Michael A Foley

Chief Executive Officer

Current

Luke Knecht

Chief Operating Officer

Current

Joseph Pearlberg

Senior Vice President

Current

James E Flynn

Managing Partner

Current

Robert Contreras

Managing Director

Current

Name

Michael A Foley

Luke Knecht

Joseph Pearlberg

James E Flynn

Robert Contreras

Work History

Title

Chief Executive Officer

Chief Operating Officer

Senior Vice President

Managing Partner

Managing Director

Status

Current

Current

Current

Current

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.